A splashy recent acquisition by the company might not be panning out. Just before the market open on Monday, AbbVie revealed that its emraclidine schizophrenia treatment did not meet its primary ...

Oct 30 (Reuters) - AbbVie (ABBV.N), opens new tab raised its annual profit forecast after strong sales of its newer immunology drugs and key cancer treatment helped the company beat Wall Street ...

In trading on Monday, shares of AbbVie crossed below their 200 day moving average of $178.81, changing hands as low as $172.70 per share. AbbVie Inc shares are currently trading down about 12.4% ...

Disappointing news from the laboratory weighed on AbbVie (NYSE: ABBV) stock as the trading week kicked off. The company had high hopes for a schizophrenia drug it was developing; however ...